Is FIB-4 the right tool for screening for liver fibrosis?
Authors:
- Leen J.M. HeyensLHLeen J.M. Heyens
- Francesco InnocentiFIFrancesco Innocenti
- Sven FrancqueSFSven Francque
- Yves KockaertsYKYves Kockaerts
- Ine LowyckILIne Lowyck
- Kirsten StinkensKSKirsten Stinkens
Open Access
- 24 December 2025
- journal article
- Published by Elsevier in Annals of Hepatology
- Vol. 31 (2) , 102176
Abstract
No abstract availableKeywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (1S73421N)
This publication has 43 references indexed in Scilit:
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive SummaryDiabetologia, 2024
- Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the PopulationClinical Gastroenterology and Hepatology, 2022
- Poor Diagnostic Efficacy of Noninvasive Tests for Advanced Fibrosis in Obese or Younger Than 60 Diabetic NAFLD patientsClinical Gastroenterology and Hepatology, 2022
- Liver biopsy for assessment of chronic liver diseases: a synopsisClinical and Experimental Medicine, 2022
- Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver DiseaseJAMA Network Open, 2019
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patientsHepatology, 2016
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortalityHepatology, 2011
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006